The combination of a beta-blocker and angiotensin-converting enzyme inhibitor (ACEi) acts on two neuroendocrine systems implicated in the pathophysiology of hypertension and multiple CVD: beta-blockers on the sympathetic nervous system and ACEis on the renin-angiotensin system (RAS). Here, ACE is linked to hypertensive disorder.